Greg Testerman
Adult Health · Independence, MONPI 1154979938
Payments from drug & device makers
Across 149 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$377
- AbbVie$318
- Lilly USA, LLC$298
- Boehringer Ingelheim$243
- AstraZeneca$226
- Takeda Pharmaceuticals U.S.A., Inc.$207
- plus $798 from 18 others
What the payments were for
- Food & beverage$2,467100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $377 |
| AbbVie | 17 | $318 |
| Lilly USA, LLC | 19 | $298 |
| Boehringer Ingelheim | 15 | $243 |
| AstraZeneca(2 entities) | 14 | $226 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $207 |
| Merck | 6 | $111 |
| Sanofi-aventis U.S. LLC | 7 | $108 |
| Biohaven Pharmaceuticals, Inc. | 5 | $106 |
| Amgen | 6 | $79 |
| Pfizer | 5 | $75 |
| Eisai Inc. | 3 | $48 |
| Currax Pharmaceuticals LLC | 3 | $42 |
| GSK | 2 | $34 |
| Johnson & Johnson | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Baxter Healthcare | 1 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $14 |
| Sanofi | 1 | $13 |
| Bayer | 1 | $13 |
| Biogen | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
How this compares
$2,467 in reported general payments places this provider in the 75th percentile of 555 adult health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 62 | $74,188 |
| EliquisApixaban | 48 | $52,073 |
| TrulicityDulaglutide | 46 | $46,968 |
| OzempicSemaglutide | 46 | $43,349 |
| MounjaroTirzepatide | 29 | $40,003 |
| XareltoRivaroxaban | 25 | $31,510 |
| JanuviaSitagliptin Phosphate | 18 | $28,523 |
| TradjentaLinagliptin | 23 | $21,840 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $12,507 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,326 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $8,825 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $7,890 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,754 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $5,220 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 15 | $4,215 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $243 | $101,78297 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $298 | $89,67286 claims |
| PfizerEliquis | $75 | $52,07348 claims |
| Novo NordiskOzempic | $377 | $43,34946 claims |
| Johnson & JohnsonXarelto | $33 | $31,51025 claims |
| MerckJanuvia | $111 | $28,52318 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arexvy | $34 | $23,43142 claims |
| AstraZenecaSymbicort | $226 | $5,22013 claims |
| AbbVieSynthroid | $318 | $2,34033 claims |
| Sanofi-aventis U.S. LLCLantus | $108 | $1,05313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 555 adult health providers in Missouri.
Other adult health in Independence
- Katie MurrayIndependence$59K
- Tabitha StithChesterfield$300K
- Stephanie VogelSaint Louis$115K
- Racquel FrisellaChesterfield$110K
- Shannon TuckerSaint Louis$93K
- Laurencia KlipfelSaint Louis$79K
- Maria WallsSaint Louis$69K
- Patrick BehnkeChesterfield$54K
- Elaine ZobristFenton$38K
- Yolanda Thompson MartinKansas City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.